Peptide Center / CJC-1295
Not FDA-approvedCJC-1295: evidence, status & safety
CJC-1295 is a long-acting growth-hormone-releasing hormone analog studied for its effects on GH and IGF-1. It is not an FDA-approved drug.
Clinical Snapshot
What patients should know first
| Commonly discussed for | Sleep, lean mass, fat loss, recovery, performance and anti-aging. |
| What efficacy data show | Small, short trials in healthy adults showed prolonged increases in GH and IGF-1. They did not establish durable improvements in body composition, injury recovery, function, healthspan or survival. |
| Approval boundary | A biomarker response is evidence of pharmacologic activity—not proof of a meaningful clinical benefit. |
| Safety context | FDA notes limited clinical data, immunogenicity and peptide-characterization concerns, and serious adverse events including increased heart rate and systemic vasodilatory reaction. |
Interpretation
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.
Questions to ask
- Is there an FDA-approved product for my exact condition?
- What human outcome—not only biomarker—supports this use?
- What are the important contraindications and stopping rules?
- Which licensed pharmacy will dispense the prescription?
- How will response and adverse effects be monitored?
Primary Sources
Verify the evidence
Evidence Before TreatmentKnow the status.
Know the status.
Verify the source.
This guide is educational and cannot determine whether CJC-1295 is appropriate for you.